Literature DB >> 1362888

Effect of 3 weeks treatment with yohimbine on salivary secretion in healthy volunteers and in depressed patients treated with tricyclic antidepressants.

H Bagheri1, L Schmitt, M Berlan, J L Montastruc.   

Abstract

The effect of yohimbine treatment (4 mg three times daily) for 3 weeks on salivary secretion was investigated. In healthy volunteers, acute administration of yohimbine increased salivary volume within 1 h to a similar extent before and at the end of the treatment period. In depressed patients treated with tricyclic antidepressants (and exhibiting a reduced salivary flow), yohimbine also acutely increased salivary volume. In contrast, the alpha 2-adrenoceptor antagonist failed to modify resting values measured in the morning (i.e. 10 and 14 h after the last administration in healthy volunteers and depressed patients respectively). This result indicates that alpha 2-adrenoceptor antagonists may have a potential therapeutic use in the treatment of dry mouth caused by tricyclic antidepressant drugs.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1362888      PMCID: PMC1381460          DOI: 10.1111/j.1365-2125.1992.tb05661.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  11 in total

1.  Yohimbine increases salivary secretion in depressed patients treated with tricyclic antidepressants.

Authors:  Y Rispail; L Schmitt; M Berlan; J L Montastruc; P Montastruc
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

2.  Yohimbine bioavailability in humans.

Authors:  S K Guthrie; M Hariharan; L J Grunhaus
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

3.  Pharmacodynamic effects of chronic yohimbine treatment in healthy volunteers.

Authors:  J Galitzky; D Rivière; M A Tran; J L Montastruc; M Berlan
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

4.  Yohimbine increases human salivary secretion.

Authors:  E Chatelut; Y Rispail; M Berlan; J L Montastruc
Journal:  Br J Clin Pharmacol       Date:  1989-09       Impact factor: 4.335

Review 5.  Yohimbine: a pharmacological probe for study of the alpha 2-adrenoreceptor.

Authors:  M R Goldberg; D Robertson
Journal:  Pharmacol Rev       Date:  1983-09       Impact factor: 25.468

6.  Effects of yohimbine on submaxillary salivation in dogs.

Authors:  P Montastruc; M Berlan; J L Montastruc
Journal:  Br J Pharmacol       Date:  1989-09       Impact factor: 8.739

7.  Yohimbine increases submaxillary kallikrein release into the saliva in dogs: evidence for alpha 2-adrenoceptor-mediated inhibition of cholinergic pathways.

Authors:  J P Girolami; J L Bascands; C Pécher; M Berlan; J L Montastruc; P Montastruc
Journal:  Br J Pharmacol       Date:  1991-02       Impact factor: 8.739

8.  Anticholinergic activity of two tricyclic antidepressants.

Authors:  B Blackwell; A Stefopoulos; P Enders; R Kuzma; A Adolphe
Journal:  Am J Psychiatry       Date:  1978-06       Impact factor: 18.112

9.  The pharmacokinetics of yohimbine in man.

Authors:  J A Owen; S L Nakatsu; J Fenemore; M Condra; D H Surridge; A Morales
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

10.  Effect of yohimbine on blood pressure in patients with depression and orthostatic hypotension induced by clomipramine.

Authors:  L Lacomblez; G Bensimon; F Isnard; B Diquet; Y Lecrubier; A J Puech
Journal:  Clin Pharmacol Ther       Date:  1989-03       Impact factor: 6.875

View more
  2 in total

1.  Pharmacokinetic study of yohimbine and its pharmacodynamic effects on salivary secretion in patients treated with tricyclic antidepressants.

Authors:  H Bagheri; P Picault; L Schmitt; G Houin; M Berlan; J L Montastruc
Journal:  Br J Clin Pharmacol       Date:  1994-01       Impact factor: 4.335

Review 2.  Salivary Secretory Disorders, Inducing Drugs, and Clinical Management.

Authors:  Jaume Miranda-Rius; Lluís Brunet-Llobet; Eduard Lahor-Soler; Magí Farré
Journal:  Int J Med Sci       Date:  2015-09-22       Impact factor: 3.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.